Date: 2014-08-13
Type of information: Grant
Company: Ablynx (Belgium)
Investors: Flemish Agency for Innovation by Science and Technology (IWT) (Belgium)
Amount: €2.1 million
Funding type: grant
Planned used: This grant will help advance a wholly-owned programme, which will explore a novel approach to the treatment of diseases of the eye by utilising some of the unique characteristics of Nanobodies. The grant is available over a period of three years and will allow the development and subsequent testing of Nanobody leads in relevant pre-clinical disease models.
Others: * On August 13, 2014, Ablynx announced that it has been awarded a €2.1 million grant by the Flemish Agency for Innovation by Science and Technology (IWT) to help advance a wholly-owned programme, which will explore a novel approach in ophthalmology.
Therapeutic area: Ophtalmological diseases
